Jinhai Medical Technology And 2 More Promising Penny Stocks
The Asian markets have been a focal point for investors as they navigate the complexities of global economic shifts, with China’s consumer inflation easing and Japan’s stock markets experiencing gains. For those interested in exploring beyond the well-trodden paths of large-cap stocks, penny stocks—despite their somewhat outdated moniker—continue to present intriguing opportunities. These smaller or newer companies can offer significant value, especially when they possess strong financial foundations and potential for growth.
Name
Share Price
Market Cap
Financial Health Rating
Oiltek International (SGX:HQU)
SGD0.635
SGD272.42M
★★★★★★
Lever Style (SEHK:1346)
HK$1.44
HK$890.67M
★★★★★★
Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)
Let’s explore several standout options from the results in the screener.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Jinhai Medical Technology Limited is an investment holding company offering minimally invasive surgery solutions, medical products, and related services in the People’s Republic of China and Singapore, with a market cap of HK$10.16 billion.
Operations: The company generates revenue from two primary regions: SGD 14.82 million from Singapore and SGD 19.83 million from the People’s Republic of China.
Market Cap: HK$10.16B
Jinhai Medical Technology, with a market cap of HK$10.16 billion, operates in China and Singapore, generating SGD 34.65 million in revenue from these regions. Despite being unprofitable and experiencing increasing losses over the past five years, the company maintains a satisfactory net debt to equity ratio of 16.5%. Recent board changes include appointing Mr. Li Bin as co-chairman, bringing over 20 years of business management experience which could influence strategic direction positively. Although Jinhai has raised additional capital to extend its cash runway beyond six months, its financial volatility has decreased significantly over the past year.
SEHK:2225 Financial Position Analysis as at Feb 2026
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Dongguan Rural Commercial Bank Co., Ltd. offers a range of banking products and services in China, with a market cap of HK$24.11 billion.
Operations: No specific revenue segments have been reported for this company.
Market Cap: HK$24.11B
Dongguan Rural Commercial Bank, with a market cap of HK$24.11 billion, has faced challenges with declining earnings over the past year and five years. Despite this, it trades at 66.4% below its estimated fair value and maintains an appropriate loans to deposits ratio of 68%, supported by primarily low-risk funding sources. Recent changes in governance include amendments to the Articles of Association and restructuring within the board’s audit committee, aiming for enhanced oversight as independent non-executive directors join the board. The bank’s asset management remains moderate with an assets to equity ratio of 12.3x, though return on equity is considered low at 6.1%.
SEHK:9889 Debt to Equity History and Analysis as at Feb 2026
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Pizu Group Holdings Limited is an investment holding company involved in the manufacturing, trading, and sales of civil explosives in the People’s Republic of China and Tajikistan, with a market cap of HK$6.44 billion.
Operations: The company generates revenue primarily from its Mining Operation, which accounts for CN¥965.07 million, and Explosives Trading and Blasting Services, contributing CN¥619.40 million.
Market Cap: HK$6.44B
Pizu Group Holdings, with a market cap of HK$6.44 billion, has shown robust earnings growth of 57.5% over the past year despite a decline in sales to CN¥748.16 million for the recent half-year period. The company’s management and board are seasoned, contributing to high-quality earnings and stable operations. While its debt is well covered by operating cash flow and interest payments are not a concern, short-term liabilities exceed assets by CN¥100 million. Trading significantly below estimated fair value, Pizu maintains satisfactory net debt levels but faces challenges with volatile share prices and low return on equity at 13.2%.
SEHK:9893 Debt to Equity History and Analysis as at Feb 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2225 SEHK:9889 and SEHK:9893.
This article was originally published by Simply Wall St.
